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ttp://dx.doi.org/10.1016/j.ajpath.2013.10.008A major limitation in the pharmacological treatment of pulmonary arterial hypertension (PAH) is the lack
of pulmonary vascular selectivity. Recent studies have identiﬁed a tissue-penetrating homing peptide,
CARSKNKDC (CAR), which speciﬁcally homes to hypertensive pulmonary arteries but not to normal pul-
monary vessels or other tissues. Some tissue-penetrating vascular homing peptides have a unique ability
to facilitate transport of co-administered drugs into the targeted cells/tissues without requiring physical
conjugation of the drug to the peptide (bystander effect). We tested the hypothesis that co-administered
CAR would selectively enhance the pulmonary vascular effects of i.v. vasodilators in Sugen5416/hypoxia/
normoxia-exposed PAH rats. Systemically administered CAR was predominantly detected in cells of
remodeled pulmonary arteries. Intravenously co-administered CAR enhanced pulmonary, but not sys-
temic, effects of the vasodilators, fasudil and imatinib, in PAH rats. CAR increased lung tissue imatinib
concentration in isolated PAH lungs without increasing pulmonary vascular permeability. Sublingual CAR
was also effective in selectively enhancing the pulmonary vasodilation by imatinib and sildenaﬁl. Our
results suggest a new paradigm in the treatment of PAH, using an i.v./sublingual tissue-penetrating
homing peptide to selectively augment pulmonary vascular effects of nonselective drugs without the
potentially problematic conjugation process. CAR may be particularly useful as an add-on therapy to
selectively enhance the pulmonary vascular efﬁcacy of any ongoing drug treatment in patients with PAH.
(Am J Pathol 2014, 184: 369e375; http://dx.doi.org/10.1016/j.ajpath.2013.10.008)Supported by NIH grants HL106101 and CA125255 (M.K.), CA152327
(E.R.), Department of Defense grant X81XWH-08-2-0032 (E.R.), American
Heart Association grant 12080100 (M.K.), FloridaBiomed grant 2KF04 (M.K.),
the Academy of Finland (T.A.H.J.), the Sigrid Juselius Foundation (T.A.H.J.),
the Finnish Medical Foundation (T.A.H.J.), the Instrumentarium Research
Foundation (T.A.H.J.), Vascular BioSciences (D.M.), and the Department of
Pharmacology and the Center for Lung Biology, University of South Alabama
(M.O. and I.F.M.).
Disclosures: D.M. is an employee and shareholder of Vascular BioSciences
and VBS Pharmaceuticals, E.R. is a shareholder of VBS Pharmaceuticals, and
M.K. and T.A.H.J. are warrant holders of VBS Pharmaceuticals.Pulmonary arterial hypertension (PAH) remains a highly
fatal syndrome, despite recent advancements in its treat-
ment.1,2 New candidate drugs, such as Rho kinase inhib-
itors3e6 and tyrosine kinase inhibitors,7,8 have shown
promise in providing improved treatment for PAH. However,
the clinical application of these agents has generally been
hampered by their systemic toxicity/adverse effects.9e12
Inhalation is a relatively selective drug delivery method for
the lungs,13 but there are several problems with the clinical
use of aerosol inhalation in the treatment of PAH.14 In fact,
insufﬁcient inhalation due to technical problems may be a
major limitation for the effectiveness of inhaled Rho kinase
inhibitor, fasudil, in patients with PAH.15stigative Pathology.
.In numerous diseases, the blood vessels in the affected
organ express disease-speciﬁc cell surface markers (vascular
zip codes).16 For example, tumor blood vessels express
Toba et aldistinctive markers not present in vessels of normal tissues.16
These target organespeciﬁc molecular structures are
detectable by systemically administered homing pep-
tides,16,17 which ﬁnd their way to the desired location by
binding to their receptor expressed in the blood vessels of the
target organ. Promising results are accumulating for the use
of homing peptides to deliver drugs selectively to
tumors.16e18 This potentially useful targeting technology has
not yet been applied to the treatment of PAH, although
vascular selectivity would be desired in PAH.
We have recently reported tumor-homing peptides that spe-
ciﬁcally bind to tumor vessels and then extravasate into the
tumor tissue, carrying a payload with them.18,19 Even more
important, a tumor-penetrating peptide can transport co-
administered drugs into the target tissue without chemically
coupling the compound with the peptide (bystander effect).20
This novel mechanism involves homing peptideeinduced
activation of an endocytic trans-tissue transport pathway, named
CendR-pathway, in the target tissue of the peptide.18e20 The
bystander effect provides the advantage of promoting delivery
of a drug to its target tissue without the coupling of the drug to
the peptide required in conventional drug targeting.20
CARSKNKDC (CAR) is a vascular homing peptide
originally identiﬁed as being capable of homing to the neo-
vasculature in injured, regenerating tissues.21 CAR requires
heparan sulfate on the target cells for cell binding and uptake
into cells,21 suggesting that this peptide may recognize a
unique sulfation pattern of heparan sulfate proteoglycans on
the target cells. When CAR is fused together with the anti-
ﬁbrotic protein, decorin, as a recombinant fusion protein, it
accumulates in the wound and penetrates deep into wound
granulation tissue.22,23 More recently, we have shown that
CAR also selectively accumulates in the walls of hyperten-
sive pulmonary arteries in monocrotaline- and Sugen5416/
hypoxia/normoxia-induced (SU/Hx/Nx) PAH rats, but not
in normotensive pulmonary arteries.24 This study also
showed that CAR penetrates beyond the vascular endothe-
lium; it accumulates in the entire wall of hypertensive pul-
monary arteries and in the surrounding lung parenchyma.24
The tissue-penetrating activity of CAR prompted us to
examine whether CAR might also induce a bystander effect,
and if it could be used to selectively transport co-administered
drugs to CAR’s homing destination (ie, PAH tissue). We have
tested the effect of CAR co-administration on three vasodila-
tors: i) the Rho kinase inhibitor, fasudil; ii) the tyrosine kinase
inhibitor, imatinib; and iii) the phosphodiesterase type 5 in-
hibitor, sildenaﬁl. They were tested on blood pressure in PAH
rats. We have also determined whether i.v. administration of
CAR could be replaced by sublingual dosing.
Materials and Methods
Animals
All experimental procedures were approved by the Institu-
tional Animal Care and Use Committee of the University of370South Alabama (Mobile). PAH was experimentally induced
in adult male Sprague-Dawley rats (weighing 204  31 and
323  30 g at the time of Sugen5416 injection and the he-
modynamic experiments, respectively; n Z 49) by s.c. in-
jection of Sugen5416 (20 mg/kg; Cayman, Ann Arbor, MI)
and exposure to hypoxia (10% O2) for 3 weeks. The rats were
then returned to normoxia (21%O2) for an additional 2 weeks
(5 weeks after the SU injection; SU/Hx/Nx PAH rats).5
Hemodynamic Measurements in Catheterized Rats
All rats were placed on controlled heating pads after theywere
anesthetized with i.p. 30 mg/kg pentobarbital sodium. He-
modynamic measurements were performed under normoxic
conditions, as previously described, with minor modiﬁca-
tions.25 Brieﬂy, polyvinyl catheters (internal diameter, 0.28
mm) were inserted into the right ventricle (RV) via the right
jugular vein for measurement of RV systolic pressure
(RVSP). RVSP, instead of pulmonary arterial pressure, was
measured, because the pulmonary artery cannot be routinely
catheterized in these severely pulmonary hypertensive rats
that have an altered structure of the RV chamber. In cases
when we have successfully catheterized the artery, we
conﬁrmed that there was no difference between RVSP and
systolic pulmonary arterial pressure (data not shown). A
microtipped P-V catheter (1.4 Fr; Millar Instruments, Hous-
ton, TX) was inserted into the right carotid artery to measure
systolic systemic arterial pressure (SAP). In some cases, the
catheter was advanced into the left ventricle to measure car-
diac output, which was derived from a pressure-volume
curve. The cardiac index (CI) was calculated by dividing
cardiac output by bodyweight. The signalswere continuously
recorded by an MPVS-300 system with PowerLab/4SP, A/D
converter (AD Instruments, Colorado Springs, CO), and a
personal computer. An additional polyvinyl catheter was
inserted into the left jugular vein for the injection of drugs.
IHC Data
Two hours after i.v. injection of 3 mg/kg ﬂuorescein-labeled
CAR in SU/Hx/Nx rats, lungs were inﬂated with formalin-
agarosemixture at a constant pressure of 20 cmH2Obefore the
ﬁxation. Immunohistochemical (IHC) staining was performed
using rabbit anti-ﬂuorescein isothiocyanate antibody (Invi-
trogen, Carpenteria, CA), followed by labeled polymere
horseradish peroxidase anti-rabbit IgG secondary antibody
(Dako EnvisonþSystem-HRP), as described previously.24
Isolated Perfused Lungs and Assessment of Endothelial
Permeability
The techniques of lung isolation, ventilation, and constant-
ﬂow perfusion with physiological salt solution (Earle’s
balanced salt solution; Sigma, St. Louis, MO) have been
described previously.5 After the blood was ﬂushed out of the
lungs with 20mL of physiological salt solution, the lungs wereajp.amjpathol.org - The American Journal of Pathology
CAR Peptide Enhances PAH Drug Efﬁcacyperfused with a recirculated volume of 30 mL. The ﬁltration
coefﬁcient (Kf) was measured under zone 3 conditions, as
previously described.26 Kf was calculated as the rate of weight
gain 13 to 15 minutes after a 7 to 10 cm H2O increase in
pulmonary venous pressure, normalized per gram of lung dry
weight. Kf, the product of speciﬁc endothelial permeability
and surface area for exchange, is a sensitive measure of lung
endothelial permeability when surface area is fully recruited.26
Measurement of Imatinib Concentration by Mass
Spectrometry
Lung tissue imatinib concentrations were measured by
MicroConstants, Inc., (San Diego, CA) in isolated salt sol-
utioneperfused lungs from SU/Hx/Nx rats. After equilibration
for 20 minutes, 3 mmol/L imatinib or 3 mmol/L imatinib and 1
mg/30 mL CAR mixture was added to the perfusate reservoir.
The lungs were ﬂushed with 30 mL of Earle’s balanced salt
solution 5 minutes after the drug administration to remove any
residual drugs and were then snap frozen and kept at 80C.
The lungs were homogenized by placing the tissue into 2-mL
Matrix tubes from MP Biomedicals (Solon, OH) and adding
PBS, pH 7.4, to the tissue, with a 3:1 ratio (v/w). The samples
were processed to a smooth homogenate using a Fastprep-24
(MP Biomedicals). Homogenized tissue samples were diluted
at least 10-fold using rat plasma with sodium heparin as the
anticoagulant. Samples (50.0 mL) containing imatinib with
imatinib-d8 as the internal standard were processed simulta-
neouslywith spiked standards in rat plasmaby adjusting the pH
with a 3% ammonia solution and extracted using a solvent
mixture of methyl tert butyl ether/hexane (4 mL; 3:1, v/v) and
vortex mixing for 5 minutes. The samples were centrifuged to
separate the aqueous and organic layers and subsequently kept
at70Cuntil the lower aqueous layerwas frozen. The organic
portions were poured into new tubes containing 25.0 mL of 4%
propylene glycol in isopropyl alcohol and dried in a TurboVap
set at 40C under a stream of nitrogen gas. The extracts were
reconstituted with 50 mmol/L ammonium formate, 0.1% for-
mic acid in water:0.1% formic acid in acetonitrile (400 mL;
10:90, v/v). Analysis was performed on a system composed of
an Agilent 1100 high-performance liquid chromatography
system coupled to aWaters Quattro Ultimamass spectrometer.
The high-performance liquid chromatography system was
ﬁtted with an Allure PFP Propyl column (100  2.1 mm in
diameter, 5 mm)maintained at 40C. The mobile phase was 50
mmol/L ammonium formate and 0.1% formic acid in water/
0.1% formic acid in acetonitrile (11:89, v/v). Imatinib and the
internal standardweremonitored using transitions of 494.71>
394.47 and 503.96 > 395.28, respectively. The cone voltage
was 50 V, and the collision energy was 23 eV.
Effects of I.V. CAR on Vasodilators
Bolus Injection
We examined short-term hemodynamic effects of the co-
administration of CAR and fasudil or imatinib in catheterizedThe American Journal of Pathology - ajp.amjpathol.orgSU/Hx/Nx PAH rats. After baseline measurements, a mixture
of 3 mg/kg CAR (dose based on previous homing studies21,24)
and 0.1, 1, 3, and 10 mg/kg fasudil at 15-minute intervals or 3
mg/kg CAR and 5 and 20 mg/kg imatinib at 15-minute
intervals was administered via left jugular vein, and the pa-
rameters were continuously monitored. At the end of mea-
surements, the hearts were dissected for calculation of RV/left
ventricle þ septum weight ratio.
Continuous Infusion
We ﬁrst determined an infusion rate of 10 mg/mL fasudil
that caused minimal reductions in SAP and RVSP in SU/
Hx/Nx rats. We then infused fasudil i.v. with and without 3
mg/mL CAR at the determined rate of 5 mL/minute using an
infusion pump in SU/Hx/Nx PAH rats and monitored the
parameters over 30 minutes.
Effects of Sublingual CAR on Vasodilator Activity
We examined the effects of sublingually administered CAR
on imatinib- and sildenaﬁl-induced vasodilation in SU/Hx/
Nx rats. Fifteen minutes after sublingual administration of 3
mg/kg ﬂuorescein-conjugated CAR, or the same volume of
the saline vehicle, 5 and 20 mg/kg imatinib at 15-minute
intervals or 3 and 30 mg/kg sildenaﬁl at 15-minute intervals
were given i.v. in anesthetized and catheterized rats. After
the hemodynamic measurements, the rats were euthanized,
and blood was ﬂushed with 30 mL of PBS. Organs were
ﬁxed for subsequent IHC analysis.
Pulmonary Vascular Permeability
Pulmonary vascular permeability was estimated by
measuring the Kf
26 in isolated perfused lungs from SU/Hx/
Nx rats. After 20 minutes of equilibration, Kf values were
measured before and 30 minutes after the addition of 1 mg/
30 mL CAR mixture.
Statistical Analysis
Values are means  SEM. Comparisons between groups
were made with the Student’s unpaired t-test. Differences
were considered signiﬁcant at P < 0.05.
Results
Occlusive Pulmonary Arterial Lesions in SU/Hx/Nx PAH
Rats Are Homing Targets of CAR
We used the SU/Hx/Nx rat model of PAH to study the effect
of CAR co-administration on the activity of vasodilators.
The SU/Hx/Nx rats had a high RVSP (102  3 mm Hg;
n Z 33) compared with control rats (24  1 mm Hg; n Z
8). Small pulmonary arteries and arterioles displayed severe,
occlusive, neointimal lesions in association with the
expression of the endothelial cell marker, von Willebrand371
Toba et alfactor, as reported previously for the PAH model.25,27
Consistent with a previous study,24 i.v. administered CAR
was detected in remodeled pulmonary arteries of SU/Hx/Nx
rats (Figure 1, H and I), but not in normal pulmonary ar-
teries (Figure 1, A and B). CAR was distributed in all layers
of the remodeled arteries. CAR produced a much lower
signal, if any, in other organs (liver, spleen, and heart),
except for the kidney, where the peptide is excreted
(Figure 1, CeG and JeN). The intensive CAR signal in the
kidney was found only in tubules, but not in other struc-
tures, such as arteries and glomeruli (Figure 1, E and L).
This supports the previous studies21,24 that the presence of
CAR in the kidneys is not the result of homing, but the fact
that all proteins/peptides with a molecular weight of <60
kDa are excreted through the kidneys.Hemodynamic Effects of Co-Administered CAR on
Vasodilators
Short-term bolus i.v. injections of fasudil alone caused
marked dose-dependent reductions in both RVSP and SAP
in anesthetized PAH rats (Figure 2A). Intravenously
injecting 3 mg/kg CAR alone had no effects on RVSP, SAP,
or CI in PAH rats (RVSP, from 99  17 to 102  19 mm
Hg; SAP, from 160  8 to 159  7 mm Hg; CI, from 123 
39 to 129  40 mL/minute per kilogram; n Z 3). Co-
administered CAR signiﬁcantly enhanced the short-term
pressure-lowering effects of fasudil on RVSP, but not on
SAP (Figure 2A). Co-administered CAR with 0.1 mg/kg
fasudil had no effect on CI when compared with fasudil
alone (Table 1).
We next studied whether CAR would potentiate the ac-
tivity of vasodilators that act through a different molecular
mechanism than the Rho kinase inhibition. Short-term i.v.Figure 1 Distribution of CAR in tissues of a normal (AeG) and an SU/Hx/Nx PA
body weight ﬂuorescein-labeled CAR. A and H: Low-power magniﬁcation images
severely remodeled pulmonary artery. CeG and JeN: Low-power magniﬁcation im
right (F and M) and left (G and N) ventricles. Arrows indicate renal arteries; arr
372bolus injections of imatinib alone induced a dose-dependent
and pulmonary preferential reduction in blood pressure
(Figure 2B), which is in agreement with our previous
report,7 although this effect may be limited to the hyper-
tensive pulmonary circulation.28 Similar to what was
observed with fasudil, co-administered CAR also effectively
enhanced imatinib-induced pulmonary, but not systemic,
vasodilation, resulting in a near pulmonary-speciﬁc vaso-
dilation at a dose of 20 mg/kg (Figure 2B). Co-administered
CAR with 20 mg/kg imatinib had no effects on CI when
compared with imatinib alone (Table 1).
Imatinib Concentration in Isolated PAH Lungs
To examine whether CAR increases drug transport into the
hypertensive lungs, we measured tissue concentrations of
imatinib in isolated, salt solutioneperfused PAH lungs. Co-
administered CARmarkedly increased imatinib levels in PAH
lung tissue compared with imatinib given alone (Figure 2C).
Continuous I.V. Infusion
To test whether a continuous infusion of a vasodilator at low
concentrations in the presence of CAR could enhance pul-
monary and reduce systemic effects of the vasodilator, we
i.v. administered a mixture of fasudil plus CAR at a low
infusion rate in PAH rats. We found that infusion of a
mixture of CAR and fasudil produced an augmented and
sustained reduction in RVSP (32.3%  7.2%; nZ 3), with
a much smaller decrease in SAP (11.7%  1.7%; n Z 3)
(Supplemental Figure S1). In contrast, infusion of fasudil
alone appeared to reduce SAP more than RVSP (18.9% 
4.8% versus 10.1%  6.1%; n Z 4 each) (Supplemental
Figure S1), although the difference was not statistically
signiﬁcant.H (HeN) rat. Samples were collected 2 hours after i.v. injection of 3 mg/kg
of lung tissue. B and I: High-power magniﬁcation images of a normal and
ages of tissues from spleen (C and J), liver (D and K), kidney (E and L), and
owheads, glomeruli. Scale bars: 100 mm.
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Figure 2 Enhancing effects of CAR on fasudil- and imatinib-induced pulmonary vasodilation and on lung tissue imatinib accumulation. Dose-response
curves to fasudil (A) and imatinib (B) (i.v., bolus), mixed with and without 3 mg/kg CAR for RVSP and SAP in SU/Hx/Nx PAH rats. Values are means 
SEM. NZ 5 to 6. *P < 0.05 versus without CAR. C: Imatinib content (ng) in 1 g lung tissue after addition of 3 mmol/L imatinib with (þ) and without () 1 mg
CAR to 30 mL perfusate of isolated perfused lungs from SU/Hx/Nx rats. N Z 5 and 4 for CARþ and CAR, respectively. yP < 0.05 versus CARe.
CAR Peptide Enhances PAH Drug EfﬁcacyLack of CAR Effects on Pulmonary Vascular
Permeability
CAR (1 mg/30 mL perfusate) did not increase the ﬁltration
coefﬁcient in isolated salt solutioneperfused PAH lungs
(from 0.026  0.003 to 0.024  0.007 mL/minute per cm
H2O per gramweight; nZ 3). In support of these ﬁndings, no
sign of lung edema formation was observed histologically.
Effects of Sublingually Administered CAR on
Vasodilators
We next tested whether CAR was active when given sub-
lingually. Sublingual administration of CAR effectively
augmented the short-term pulmonary vasodilatory effect of
imatinib (Figure 3A). The activity of sildenaﬁl was similarly
augmented by sublingual CAR (Figure 3B). Histological
analysis of the tissues revealed a CAR signal in all layers of the
remodeled pulmonary arteries 1 hour after sublingual admin-
istration of CAR to PAH rats (Figure 3, C and D). Similar to
the ﬁndings with i.v. injections, a much lower signal, if any,
was found for CAR in other organs (liver and spleen), except
for the excretion route, kidneys (Figure 3, EeG).Discussion
We show herein that simple co-administration of the
vascular homing peptide, CAR, which targets PAH vascula-
ture, signiﬁcantly enhances the short-term blood pressuree
lowering effects of vasodilator drugs onRVSP,but not onSAP,
in PAH rats. Our results potentially provide a new paradigm forTable 1 Cardiac Index Before and After i.v. Injection of Agents
Agent Before injection After injection
CAR (n Z 5) 123  39 129  40
Fasudil (n Z 3) 116  7 129  7
CAR þ fasudil (n Z 3) 90  7 103  6
Values are means  SEM mL/minute per kilogram.
The American Journal of Pathology - ajp.amjpathol.orgtarget tissueespeciﬁc pharmacological intervention in PAH
(Supplemental Figure S2).
CAR is a cell- and tissue-penetrating homing peptide, as
shown by the accumulation of CAR inside cultured cells,
penetrating deep into granulation tissue in wounds and into the
walls of remodeled pulmonary vessels in PAH rats.21e24 The
homing of CAR is speciﬁc for hypertensive pulmonary ves-
sels,24 because it does not accumulate in normal tissues,
including normal pulmonary arteries.21,24 We initially tried to
make use of the tissue-penetrating properties of CAR in drug
delivery by coupling a drug (fasudil) to the peptide. However,
the coupling inactivated the drug (M. Oka and E. Ruoslahti,
unpublished results). We then tested a different strategy, the
bystander effect (ie, co-administration of the drug with the
peptidewith nophysical coupling of the two to each another).20
Our approach was inspired by the recent demonstration that
another tissue-penetrating peptide (iRGD; single amino acid
code: CRGDKGPDC) could be used in thismanner to enhance
drug delivery into its target organ, tumors.20 There are some
differences in the tissue-penetration mechanism of the two
peptides: iRGD activates an endocytic trans-tissue transport
pathway dependent on neuropilin-1,18e20 whereas CAR uses
another, yet to be deﬁned, pathway, which involves binding to
the heparan sulfate proteoglycans on the cell surface.21 How-
ever, the functions of the two peptides appear to be similar
because we ﬁnd that, as has been shown for various drugs co-
administered with iRGD in tumors,20 CAR enhances the
accumulation of co-administered imatinib in its target tissue,
the PAH vasculature (Supplemental Figure S2).
Orally administered peptides are readily degraded by
digestive tract peptidases, and their oral bioavailability is poor.
Thus, direct i.v. injection remains the most common and
effective means of administering therapeutic peptides. How-
ever, an oral route would be the preferred route because of its
high level of patient acceptance and long-term compliance,
both factors that increase the therapeutic value of the drug.
Peptides that have a cyclic conformation and contain disulﬁde
bonds tend to be more resistant to peptidases than linear
peptides.29 Thus, the disulﬁde-bonded, cyclic structure of
CAR may provide a certain degree of resistance to proteases.373
Figure 3 Effects of sublingually administered CAR. Effects of sublingually administered 3 mg/kg CAR on i.v. (bolus) imatinib-induced (A) and sildenaﬁl-
induced (B) reduction in RVSP and SAP in SU/Hx/Nx PAH rats. Values are means  SEM. NZ 4 to 6. *P < 0.05 versus without CAR. Distribution of sublingually
administered CAR: a pulmonary artery with medial thickening (C), a small pulmonary artery with neointimal occlusion (D), liver (E), spleen (F), and kidney (G)
from an SU/Hx/Nx rat. Arrow indicates renal artery; arrowhead, glomerulus. Scale bars: 100 mm.
Toba et alBecause the sublingual region has lower enzyme activity than
the digestive tract,30 we tested sublingual administration of
CAR and found that CAR effectively augmented the short-
term pulmonary vasodilatory effect of imatinib and sildenaﬁl
and, similar to intravenously administered CAR, the peptide
predominantly accumulated in the PAH vasculature. These
results suggest that activeCAR peptide can be absorbed via the
sublingual mucosa to reach the target organ, hypertensive
lungs. Surprisingly, sublingual CARwas as effective as bolus-
injected CAR, suggesting the superiority of the sublingual
route as the most practical route of CAR administration.
We have shown that CAR homes to hypertensive pul-
monary arteries of two different preclinical models of pul-
monary hypertension (monocrotaline and SU/Hx/Nx rats).24
Furthermore, CAR binding and uptake to human cells and
tissue xenografts has been shown.24 However, additional
studies are warranted to examine if CAR works similarly in
human PAH as in the rat model of PAH.
Other limitations of our study stem from the peptide na-
ture of CAR, an unknown half-life in circulation, and sus-
ceptibility to proteases. These factors could make i.v./oral
administration impractical, except in the management of
acute crises in a hospital setting. The successful sublingual
administration of CAR may provide a solution to these
limitations.
We have demonstrated that the vascular homing peptide,
CAR, selectively binds to the hypertensive pulmonary374arteries, and that it penetrates into the endothelium and
ﬁbrotic tissue of the severely remodeled pulmonary arterial
wall in a rat model of PAH, which closely mimics the
human disorder. Simple co-administration of CAR selec-
tively enhances the pulmonary vascular effects of various
systemically administered vasodilators (ie, fasudil, imatinib,
and sildenaﬁl). The peptide increases the lung tissue imati-
nib concentration in isolated perfused PAH lungs, presum-
ably because CAR facilitates transport of co-administered
drugs into PAH tissue, without increasing pulmonary
vascular permeability. More important, our results suggest
that CAR is active when sublingually administered, poten-
tially providing a more practical route of administration of
CAR than i.v. injections. These ﬁndings potentially have
high clinical signiﬁcance for the treatment of PAH, because
CAR enables decreasing drug dosage to reduce its systemic
adverse effects without decreasing the pulmonary efﬁcacy
of the drug, which has never been achieved by any other
means. Our results open the door to a new direction of PAH
treatment and warrant further investigations.Acknowledgments
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